Germline DNMT3A mutation in familial acute myeloid leukaemia - PubMed

Germline DNMT3A mutation in familial acute myeloid leukaemia - PubMed

Germline DNMT3A mutation in familial acute myeloid leukaemia

Courtney D DiNardo 1, Hannah C Beird 2, Marcos Estecio 3 4, Swanand Hardikar 3 4, Koichi Takahashi 1, Sarah A Bannon 5 6, Gautam Borthakur 1, Elias Jabbour 1, Curtis Gumbs 2, Joseph D Khoury 4, Mark Routbort 4, Ting Gong 3 4, Kimie Kondo 3 4, Hagop Kantarjian 1, Guillermo Garcia-Manero 1, Taiping Chen 3 4, P Andrew Futreal 2

Affiliations 

• PMID: 32856987
 
• DOI: 10.1080/15592294.2020.1809871

Abstract

Acute myeloid leukaemia (AML) is a heterogeneous myeloid malignancy characterized by recurrent clonal events, including mutations in epigenetically relevant genes such as DNMT3A, ASXL1, IDH1/2, and TET2. Next-generation sequencing analysis of a mother and son pair who both developed adult-onset diploid AML identified a novel germline missense mutation DNMT3A p.P709S. The p.P709S protein-altering variant resides in the highly conserved catalytic DNMT3A methyltransferase domain. Functional studies demonstrate that the p.P709S variant confers dominant negative effects when interacting with wildtype DNMT3A. LINE-1 pyrosequencing and reduced representation bisulphite sequencing (RBBS) analysis demonstrated global DNA hypomethylation in germline samples, not present in the leukaemic samples. Somatic acquisition of IDH2 p.R172K mutations, in concert with additional acquired clonal DNMT3A events in both patients at the time of AML diagnosis, confirms the important pathogenic interaction of epigenetically active genes, and implies a strong selection and regulation of methylation in leukaemogenesis. Improved characterization of germline mutations may enable us to better predict malignant clonal evolution, improving our ability to provide customized treatment or future preventative strategies.

Keywords: AML; DNMT3A; germline; hereditary; predisposition.

Similar articles

• Immunohistochemical loss of 5-hydroxymethylcytosine expression in acute myeloid leukaemia: relationship to somatic gene mutations affecting epigenetic pathways.

  Magotra M, Sakhdari A, Lee PJ, Tomaszewicz K, Dresser K, Hutchinson LM, Woda BA, Chen BJ.Histopathology. 2016 Dec;69(6):1055-1065. doi: 10.1111/his.13046. Epub 2016 Sep 23.PMID: 27458708
• Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.

  Bhatnagar B, Eisfeld AK, Nicolet D, Mrózek K, Blachly JS, Orwick S, Lucas DM, Kohlschmidt J, Blum W, Kolitz JE, Stone RM, Bloomfield CD, Byrd JC.Br J Haematol. 2016 Oct;175(2):226-236. doi: 10.1111/bjh.14254. Epub 2016 Aug 1.PMID: 27476855 Free PMC article.
• Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.

  Sasaki K, Kanagal-Shamanna R, Montalban-Bravo G, Assi R, Jabbour E, Ravandi F, Kadia T, Pierce S, Takahashi K, Nogueras Gonzalez G, Patel K, Soltysiak KA, Cortes J, Kantarjian HM, Garcia-Manero G.Cancer. 2020 Feb 15;126(4):765-774. doi: 10.1002/cncr.32566. Epub 2019 Nov 19.PMID: 31742675
• Epigenetic Guardian: A Review of the DNA Methyltransferase DNMT3A in Acute Myeloid Leukaemia and Clonal Haematopoiesis.

  Chaudry SF, Chevassut TJ.Biomed Res Int. 2017;2017:5473197. doi: 10.1155/2017/5473197. Epub 2017 Feb 14.PMID: 28286768 Free PMC article. Review.
• The role of mutations in epigenetic regulators in myeloid malignancies.

  Shih AH, Abdel-Wahab O, Patel JP, Levine RL.Nat Rev Cancer. 2012 Sep;12(9):599-612. doi: 10.1038/nrc3343. Epub 2012 Aug 17.PMID: 22898539 Review.